Clinical Trial

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated December 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations. The main questions it aims to answer are: * Pharmacokinetic (PK) characteristics of WX390 combined with Toripalimab treatment. * Safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-03; most recent amendment 2024-12-09.
Trial Details
NCT Number NCT06124963
Lead Sponsor Shanghai Jiatan Pharmatech Co., Ltd
Conditions Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
Enrollment 20 participants
Start Date 2023-08-25
Primary Completion 2025-12-12 (estimated)
Study Completion 2026-12-09 (estimated)
Updated on ClinicalTrials.gov 2024-12-10